Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02345070 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 327
- Enrollment target
NCT02345070 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 327 participants.
The verdict
NCT02345070, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 327 participants
- Enrollment target
Study Summary
Primary Objective: To evaluate, in comparison with placebo, the efficacy of 2 dose levels/regimens of SAR156597 administered subcutaneously during 52 weeks on lung function of participants with Idiopathic Pulmonary Fibrosis (IPF). Secondary Objectives: To evaluate the efficacy of 2 dose levels/regimens of SAR156597 compared to placebo on IPF disease progression. To evaluate the safety of 2 dose levels/regimens of SAR156597 compared to placebo in participants with IPF.
Interventions
- DRUG placebo
- DRUG SAR156597
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 327 participants |
| Start Date | 2015-05-01 |
| Est. Completion | 2017-08-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02345070
The ClinicalTrials.gov registry entry for NCT02345070 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 327 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02345070 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02345070 about?
NCT02345070 is a clinical study titled "Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis". Primary Objective: To evaluate, in comparison with placebo, the efficacy of 2 dose levels/regimens of SAR156597 administered subcutaneously during 52 weeks on lung function of participants with Idiopathic Pulmonary Fibrosis (IPF). Secondary Objectives: To evaluate the efficacy of 2 dose levels/re...
What is the current status of trial NCT02345070?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 327 participants. The study started on 2015-05-01. Estimated completion is 2017-08-14.
What interventions are being tested in trial NCT02345070?
The interventions under investigation include: placebo (DRUG), SAR156597 (DRUG).
Who is sponsoring clinical trial NCT02345070?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.